文献速递药物不良反应与药物警戒

非维生素K拮抗剂口服抗凝药与血管性水肿:队列与病例交叉研究

Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study.
PubMed 文献 · Drug Saf · 2019-01-01

本研究利用三个大型数据库,采用队列设计比较房颤患者启用NOAC与华法林后6个月内血管性水肿的相对发生率,并用病例交叉设计比较华法林使用者与非使用者。队列研究显示NOAC与华法林相比血管性水肿风险无显著差异(HR 0.98,95%CI 0.76-1.27),病例交叉分析结果亦无显著关联(OR 0.91,95%CI 0.68-1.21)。

要点

  • NOAC与华法林相比,6个月内血管性水肿发生率无显著差异。
  • 病例交叉设计未发现华法林与血管性水肿存在显著关联。
  • 结果不支持口服抗凝药短期显著增加血管性水肿风险。

核心结论

  • NOAC与华法林相比,短期血管性水肿相对发生率无显著升高。
  • 华法林使用与血管性水肿的关联在病例交叉设计中亦无统计学意义。

研究设计与样本

  • 队列研究:从Truven Health MarketScan、Optum Clinformatics及Medicare数据库纳入新使用NOAC(达比加群、利伐沙班、阿哌沙班)或华法林的房颤患者,比较6个月内血管性水肿发生率。
  • 病例交叉研究:以自身对照设计比较华法林使用者与非使用者,控制时间恒定混杂因素。
  • 采用倾向评分分层调整混杂,随机效应模型合并各数据库HR。

主要发现

  • 队列研究共观察249例 incident 血管性水肿事件,NOAC起始者267,681例,华法林起始者281,143例。
  • Meta分析HR为0.98(95%CI 0.76-1.27),NOAC vs 华法林。
  • 病例交叉研究基于431例病例,OR为0.91(95%CI 0.68-1.21)。

临床怎么用

  • 临床处方NOAC或华法林时,无需因血管性水肿风险差异而优先选择某一类药物。
  • 对于有血管性水肿病史的患者,仍应个体化评估抗凝方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients taking non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban have reported experiencing angioedema in randomized trials and routine care. OBJECTIVE: The aim of this study was to quantify the association between NOACs and angioedema relative to warfarin among routinely treated patients with atrial fibrillation in a cohort study. We also compared warfarin users with non-users in a case-crossover study. METHODS: We utilized a cohort design that drew eligible patients from the Truven Health MarketScan Commercial database, the Optum© Clinformatics® Data Mart, and Medicare. Within each database, we compared the 6-month relative rate of angioedema among new users of NOACs (dabigatran, rivaroxaban, apixaban) and new users of warfarin. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for confounders using propensity score stratification, and meta-analyzed the database-specific HRs using a random-effects model. We also estimated an odds ratio (OR) for the association between warfarin and angioedema using a case-crossover design, a self-controlled design that controls for time-invariant confounders. RESULTS: In the cohort study, we observed 249 incident angioedema events among 267,681 NOAC initiators and 281,143 warfarin initiators across all databases. The meta-analyzed HR for angioedema comparing any NOAC versus warfarin was 0.98 (95% CI 0.76-1.27). In the case-crossover design, the OR for the association between warfarin and angioedema was 0.91 (95% CI 0.68-1.21) based on 431 cases. CONCLUSIONS: Our estimates were inconsistent with substantial short-term relative increases in the rate of angioedema associated with oral anticoagulant therapy.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Connolly JG, Schneeweiss S, Glynn RJ, et al. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019. PMID: 31321714. doi:10.1007/s40264-019-00852-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。